Eric Jonasch
Houston oncologist who led the trial that established belzutifan, the first drug for the tumours of von Hippel-Lindau disease, including kidney cancers, pancreatic tumours and haemangioblastomas.
Overview
Eric Jonasch is a genitourinary medical oncologist at MD Anderson Cancer Center and directs its von Hippel-Lindau clinical centre. He was first author of the 2021 New England Journal of Medicine report of the phase 2 trial in which the HIF-2α inhibitor belzutifan shrank renal cell carcinomas and also pancreatic lesions and central nervous system haemangioblastomas in patients with VHL disease, leading to the first approval of a drug for the syndrome.
Similar pages
not linked directly; found by shared links- PersonJan A. Burger
Shares MD Anderson Cancer Center and the tags targeted-therapy, trialist.
- PersonAleksandar Sekulic
Shares the tags targeted-therapy, trialist.
- PersonAlice T. Shaw
Shares the tags targeted-therapy, trialist.
- PersonAndrea Sartore-Bianchi
Shares the tags targeted-therapy, trialist.
- PersonGregory J. Riely
Shares the tags targeted-therapy, trialist.
- PersonJennifer A. Chan
Shares the tags targeted-therapy, trialist.
- PersonJohn H. Strickler
Shares the tags targeted-therapy, trialist.
- PersonJosé Baselga
Shares the tags targeted-therapy, trialist.